GLP-1 and Insurance Coverage: Navigating Prior Authorizations and Appeals

The Prior Authorization Process

Prior authorization — sometimes called prior approval or precertification — is a utilization management tool that requires your healthcare provider to obtain insurance company approval before the medication is dispensed. The process exists to ensure appropriate use and control costs, but it is widely acknowledged to be burdensome and a source of significant delays in care.

When your provider submits a prior authorization request, the insurance company reviews clinical information — your diagnosis, HbA1c values, current medications, and documented history of trying and failing alternative therapies. The reviewer applies clinical criteria specific to the medication's approved indications to determine whether coverage should be approved.

Prior authorization turn-around times vary, but the process typically takes 3-5 business days for standard requests and 24-72 hours for urgent requests. During this period, your prescription is essentially on hold — and if it is ultimately denied, you need a clear understanding of your appeal rights.

Common Reasons for Prior Authorization Denial

Denials for GLP-1 prior authorizations typically fall into several categories. The most common is inadequate documentation of the medical necessity — missing HbA1c values, incomplete medication history, or failure to document that step therapy requirements have been met.

Another common reason is prescribing for an indication not covered by your plan — for example, prescribing semaglutide specifically for weight loss when your plan only covers it for diabetes management. In this case, your provider may need to document the diabetes diagnosis and clinical justification more clearly, or you may need to pursue a formulary exception.

Some denials reflect formulary restrictions — the plan does not cover the specific medication prescribed and requires a preferred alternative. Others reflect contract exclusions — the plan explicitly excludes obesity medications from coverage, regardless of clinical indication.

Filing an Appeal

If your prior authorization is denied, you have the right to appeal. Insurance companies are required to provide a clear explanation of the denial and instructions for filing an appeal. There are typically multiple levels of appeal — an internal appeal to the insurance company itself, and if that fails, an external review by an independent organization approved by your state insurance department.

The internal appeal is your first step. Your provider's office typically initiates this, submitting additional clinical documentation, peer-to-peer consultation with the insurance company's medical director, or clarification of the coverage criteria and why they are met in your specific case.

For GLP-1 medications specifically, successful appeals often include documentation of cardiovascular disease history (which now supports coverage for semaglutide under Medicare), documented medication intolerance or treatment failure on preferred alternatives, and clinical evidence that the specific medication prescribed offers advantages over formulary-preferred alternatives for your individual situation.

Peer-to-Peer Reviews

Many insurance companies offer peer-to-peer consultation — a telephone conversation between your prescribing provider and the insurance company's medical director or reviewer. This can be more effective than paperwork alone, because your provider can explain the clinical nuances of your case directly to a licensed physician who has decision-making authority.

Preparing for a peer-to-peer review involves having your provider gather relevant clinical data: recent HbA1c, current medications and allergies, documented side effects or contraindications to alternative medications, and any comorbidities (cardiovascular disease, kidney disease, history of hypoglycemia) that make a specific GLP-1 agent particularly appropriate.

Patient Assistance Programs

If insurance coverage proves impossible to obtain, patient assistance programs may offer an alternative pathway to medication access.

Manufacturer assistance programs — offered by Novo Nordisk (Ozempic, Wegovy, Rybelsus) and Eli Lilly (Mounjaro, Zepbound) — provide medications at reduced or no cost to eligible patients who meet income criteria. Eligibility typically requires being a US resident, having no prescription drug coverage or being underinsured, and meeting income thresholds (usually at or below 400-500% of the federal poverty level, though criteria vary by program).

These programs require application through the manufacturer's website, with income documentation and healthcare provider attestation. Processing times vary but can take several weeks. Patients in urgent need should inquire about expedited processing if clinically appropriate.

Nonprofit patient assistance programs, such as those operated by the PAN Foundation, HealthWell Foundation, and Patient Access Network, also provide financial assistance for GLP-1 medications. These programs typically have disease-specific eligibility criteria (for example, a diagnosis of type 2 diabetes) and income requirements.

Tips for Improving Your Chances of Coverage

Several practical strategies can improve your odds of getting GLP-1 coverage approved. Start by understanding your plan's specific criteria — call the member services number on your insurance card and ask specifically what documentation is required for GLP-1 coverage.

Ensure your provider submits complete prior authorization requests the first time. Missing information is the most common preventable cause of denial. Ask your provider's office to confirm all required fields are completed and supporting documentation is attached.

Document your medication history completely. If you have tried and failed metformin, sulfonylureas, or other alternatives, these trials should be documented in your medical record with start dates, doses, and documented reasons for discontinuation.

If you have comorbidities that strengthen your case — cardiovascular disease, history of heart attack or stroke, chronic kidney disease, NAFLD/NASH — ensure these are prominently documented. The cardiovascular and renal benefits of GLP-1 therapy now support medical necessity arguments in ways they did not just a few years ago.

Finally, be persistent. Coverage denials are common on the first submission, and successful appeals are achievable with the right documentation and persistence. Work with your healthcare provider's office to understand the timeline and process, and do not accept an initial denial as the final word.

The PeptPro app helps you track your medications, HbA1c values, and other health metrics — important data for both clinical care and insurance documentation. Use it to maintain the records that support your coverage case. Track your GLP-1 journey with PeptPro — https://peptpro.io